Anne Kennedy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Kennedy has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Alvin Farrel
Divison of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA
26 shared publications - Colleen E. Casey
The Children's Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research, Philadelphia, PA, USA
26 shared publications - Denis O. Okumu
University of North Carolina at Chapel Hill 2 Department of Pharmacology Chapel Hill, North Carolina
26 shared publications - Esther R. Berko
Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
26 shared publications - Gabriela M. Witek
Division of Oncology and Center for Childhood Cancer Research, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
26 shared publications - Gary L. Johnson
University of North Carolina at Chapel Hill 1 Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina
26 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Figure S6 shows MIB/MS kinome data for COG-N-453x tumor lysates treated with crizotinib for 30 minutes.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Figure S6 shows MIB/MS kinome data for COG-N-453x tumor lysates treated with crizotinib for 30 minutes.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S17 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Figure S17 shows lorlatinib displaces MYCN and pol II from promoters of G2/M kinases.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S17 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Figure S17 shows lorlatinib displaces MYCN and pol II from promoters of G2/M kinases.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Figure S15 shows chromatin immunoprecipitation sequencing assay whereby MYCN binds to promoters of several G2/M kinases.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Figure S15 shows chromatin immunoprecipitation sequencing assay whereby MYCN binds to promoters of several G2/M kinases.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Figure S11 shows Lorlatinib downregulates AURKA expression.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Figure S11 shows Lorlatinib downregulates AURKA expression.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Table S3 shows oligonucleotide sequences of ChIP primers.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Table S3 shows oligonucleotide sequences of ChIP primers.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Methods includes supplementary material and methods and references.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Methods includes supplementary material and methods and references.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Data 1 includes the raw, unproccessed mass spectrometry label free quantification results of MaxQuant/Andromeda searches for "proteingroups."
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Data 1 includes the raw, unproccessed mass spectrometry label free quantification results of MaxQuant/Andromeda searches for "proteingroups."
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Figure S2 shows MIB/MS profiling in neuroblastoma models upon treatment with lorlatinib.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Figure S2 shows MIB/MS profiling in neuroblastoma models upon treatment with lorlatinib.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Table S4 shows RNA-seq fold changes of differentially expressed genes shared between crizotinib vs vehicle and lorlatinib vs vehicle contrasts for non kinase genes.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Table S4 shows RNA-seq fold changes of differentially expressed genes shared between crizotinib vs vehicle and lorlatinib vs vehicle contrasts for non kinase genes.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Figure S4 shows that COG-N-424x, a wild type ALK PDX, does not downregulate G2/M kinases upon ALK inhibition.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Supplementary Figure S4 shows that COG-N-424x, a wild type ALK PDX, does not downregulate G2/M kinases upon ALK inhibition.